Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Aug;71(8):947-9.
doi: 10.1001/jamaneurol.2014.1120.

Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point

Richard J Kryscio  1
Affiliations
Editorial

Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point

Richard J Kryscio. JAMA Neurol. 2014 Aug.
No abstract available

PubMed Disclaimer

Comment on

  • The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
    Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Cooperative Study. Donohue MC, et al. JAMA Neurol. 2014 Aug;71(8):961-70. doi: 10.1001/jamaneurol.2014.803. JAMA Neurol. 2014. PMID: 24886908 Free PMC article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pillai JA, Cummings JL. Clinical trials in predementia stages of Alzheimer disease. Med Clin North Am. 2013;97(3):439–457. - PubMed
    1. Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurology. to appear. - PMC - PubMed
    1. Kryscio RJ, Mendiondo MS, Schmitt FA, Markesbery WR. Designing a large prevention trial: statistical issues. Stat Med. 2004;23:285–296. - PubMed
    1. Carrillo MC, Brashaer R, Logovinsky V, et al. Can we prevent Alzheimer's disease secondary “prevention” trials in Alzheimer's disease. Alzheimers Dement. 2013;9(2):123–131. - PubMed
    1. Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc. 2008;14(2):266–278. - PMC - PubMed

Substances